Fibroblast growth factors connect molecular signaling to processes such as cell growth, proliferation, tissue repair, and developmental regulation. Among them, fibroblast growth factor 2 (FGF2) is valuable for biomedical and applied research, but its β-barrel structure, built from β-pleated sheets and connecting loops, makes it a difficult recombinant target. In heterologous hosts, stable accumulation, proper folding, and efficient recovery of FGF2 cannot be assumed simply because the gene is transcribed and translated. The production challenge is also due to the limitations of current expression systems. Natural isolation from mammalian cells yields only limited quantities and raises biological and ethical concerns. On the other hand, bacterial and yeast platforms can produce recombinant proteins, but they depend on organic nutrient inputs, fermentation infrastructure, and culture conditions that may increase contamination risk. In contrast, photosynthetic organisms can provide an attractive alternative because they can grow without externally supplied organic carbon, however, plants and eukaryotic algae introduce other complications such as slow growth, more demanding transformation procedures, low expression, and degradation of non-native proteins by intracellular proteolytic systems. Synechocystis sp. PCC 6803 provides a different biological setting for this problem. As a unicellular cyanobacterium, it combines photosynthetic growth with stable genetic transformation, which makes it useful for synthetic biology approaches that seek to couple recombinant production with native cellular machinery. A central feature of Synechocystis is the phycobilisome light-harvesting apparatus, in which the highly expressed phycocyanin β-subunit CpcB forms part of a native photosynthetic structure required for efficient light capture and growth.

In a recent research paper published in ACS Synthetic Biology, postdoctoral fellow Dr. Bharat Kumar Majhi and Professor Anastasios Melis from the University of California Berkeley addressed this problem by asking whether FGF2 could be stabilized in Synechocystis through fusion to the phycocyanin β-subunit. They tested whether the abundance of a native photosynthetic protein could be used to support the accumulation, recovery, and functional retention of a structurally demanding growth factor. Briefly, Majhi and Melis designed two fusion constructs in which a codon-optimized bovine FGF2 sequence was placed in frame with cpcB within the native phycocyanin operon. One construct contained FGF2 without the eight-amino-acid N-terminal signaling segment, whereas the other retained this segment. In both designs, the modified CpcB protein carried a 6xHis tag, a short spacer, and a TEV protease recognition sequence before the FGF2 portion. By inserting FGF2 at the carboxyl-terminal side of CpcB while preserving a cleavable junction, the design tied FGF2 accumulation to a highly expressed photosynthetic protein and, at the same time, left open a route for later release of the growth factor from the fusion.

The authors found the transformed Synechocystis strains reached genomic DNA homoplasmy, as judged by PCR products corresponding to the modified loci and absence of the wild-type cpc operon product. Homoplasmy was important because mixed wild-type and transgenic genome copies would complicate physiological and biochemical interpretation. Once the strains were established, they remained capable of photoautotrophic growth, although their doubling times were slower than wild type under the subsaturating irradiance used for cultivation. The Syn*FGF2 and Syn*N*FGF2 strains doubled in about 42 and 50 hours, respectively, compared with about 28 hours for wild type. Their greener appearance and spectral profiles reflected reduced phycocyanin content, calculated at about 18.2% of the wild-type level after correction with the phycocyanin-lacking reference strain. The interpretation offered in the paper is structurally precise: the transformants appear to assemble only the proximal phycocyanin disc containing the modified Phyco*FGF2 β-subunit, rather than the full complement of middle and peripheral phycocyanin discs.

In wild-type cells, Majhi and Melis found the expected abundant phycocyanin CpcB band to be present at about 19 kDa while in the transformants, that band disappeared and was replaced by new bands at approximately 36 and 37 kDa, corresponding to Phyco*FGF2 and Phyco*N*FGF2. Zinc chromophore labeling confirmed that these bands retained the phycocyanobilin-associated character of phycocyanin, while Western blotting with FGF2 antibodies confirmed the presence of the FGF2 component. A secondary band near 30 kDa, also positive by zinc labeling and FGF2 immunoreactivity, was interpreted as an aberrantly migrating fraction of the fusion protein, consistent with the unusual behavior expected from an FGF2-containing construct. The critical comparison was with the nonfusion FGF2, expressed by itself under the cpc promoter: without fusion to CpcB, only trace FGF2 accumulated. Fusion to CpcB therefore changed the biological outcome from marginal detection to dominant accumulation. They isolated His-tagged fusion protein complexes from crude cyanobacterial lysates by cobalt affinity chromatography as modified heterohexameric phycocyanin disc complexes containing CpcA, the CpcG1 linker, and the CpcB-FGF2 fusion. Treatment with recombinant TEV protease progressively reduced the 36–37 kDa fusion band and produced the expected CpcB-derived cleavage fragment, with FGF2 migrating near the CpcA band and western blotting analysis showed that the 17 kDa FGF2 signal appeared only after TEV treatment. The authors’ fusion design therefore had a direct scientific consequence: it stabilized FGF2 during cyanobacterial expression as well as preserved the protease-accessible junction for recovery of the natural-size growth factor. They also tested biological activity using human embryonic kidney cells and found the isolated Phyco*FGF2 and Phyco*N*FGF2 complexes retained signaling activity relative to commercial natural FGF2 confirming that the cyanobacterial production strategy preserved its functional activity properties.

The two fusion versions behaved similarly in this assay, since the presence or absence of the eight-amino-acid N-terminal segment did not produce a discernible difference. Preliminary heat-treatment experiments also indicated retention of activity after 24 hours, suggesting that the phycocyanin disc environment may confer functional stability to the FGF2 moiety. A preliminary process analysis estimated Phyco*(N)*FGF2 at about 14% of biomass and cleaved isolated FGF2 at about 1.4% of biomass, with the authors treating these yield values cautiously because they were based on Coomassie staining.

A central innovation of the work of Professor Anastasios Melis and Dr. Bharat Kumar Majhi is the use of phycocyanin as a stabilizing carrier for FGF2 and such design is scientifically important because it links a structurally difficult growth factor to a native photosynthetic protein that the host cell naturally produces and incorporates into its light-harvesting machinery. In this way, the researchers used a native abundance pathway to support recombinant protein accumulation. The study therefore provides a useful synthetic-biology model for producing difficult growth factors in photosynthetic microbial hosts, with potential value for research systems that require accessible, functional, and recoverable biomedical proteins.

 

Reactive oxygen species accumulate when amyloid deposition and inflammatory signaling reinforce one another, and under those conditions microglia drift away from debris clearance and repair toward a state that feeds neuronal stress. That shift has been recognized for years in Alzheimer’s disease, but it has remained difficult to decide whether changing microglial phenotype can do more than transiently quiet inflammation.    Microglia do not just react to amyloid deposits as passive bystanders. They read protein aggregates, stress signals, and cytokine cues, and then choose from functional programs that can differ sharply in consequence. A pro-inflammatory program amplifies cytokine release, nitric oxide production, and oxidative injury; a repair-oriented program supports resolution and tissue maintenance. The difficulty is that these programs are not clean switches in diseased tissue. They are shaped by continuous exposure to fibrillar β-amyloid, by oxidative pressure, and by receptor systems such as TLR4 that can convert extracellular pathology into intracellular inflammatory signaling. When that loop persists, NOX2-derived oxidants help keep NF-κB activity alive, and the brain pays the price in synaptic and neuronal vulnerability. In a recent research paper published in Theranostics, Dr. Jun Xie, Kai Cao, Dr. Luman Liu, Dr. Liding Zhang, Dr. Ying Yang, Dr. Hui Gong, and Professor Haiming Luo from the Wuhan National Laboratory for Optoelectronics at Huazhong University of Science and Technology, developed a water-soluble Mn3O4 nanozyme modified for intranasal delivery and brain access. They used it as a catalytic antioxidant to suppress TLR4/NOX2-associated ROS production and shift microglia toward an M2-like state.

The research team began by building a water-soluble Mn3O4 nanozyme through PEG-lipid modification of a small hausmannite Mn3O4 core. They measured a core size near 4.8 nm, observed a larger hydrodynamic diameter in water, and found that the material behaved mainly as a superoxide-dismutase-like catalyst while also scavenging superoxide and hydroxyl radicals. A broad but not unlimited antioxidant repertoire gave the investigators a tool capable of testing whether selective oxidant control was enough to push microglia away from inflammatory bias. They then challenged N9 microglia with LPS, identified 2 μg/mL as an effective condition for M1-skewing, and showed that the nanozyme suppressed the rise in the CD86/CD206 ratio without introducing appreciable toxicity at the concentrations carried into the phenotype experiments. The investigators also tracked the response over time, which turned out to be informative: LPS drove a pronounced rise in the M1/M2 marker ratio around 24 hours, while nanozyme pretreatment blunted that shift instead of abolishing it outright.

The authors then moved into mouse models in a way that tightened the mechanistic argument. In an acute hippocampal LPS model, they selected an injection dose that maximized M1 polarization and paired it with intranasal nanozyme administration. They confirmed that the material reached the brain within hours, distributed beyond the nasal cavity, and was largely cleared from the body within 36 hours, while hemolysis and routine liver and kidney chemistry did not reveal acute toxicity. In the inflamed hippocampus, the investigators observed lower CD86, higher CD206, reduced TLR4 abundance, and recovery of NeuN-positive neuronal signal after nanozyme treatment.

The researchers then turned to the 5×FAD mouse model and documented elevated TLR4 expression in the diseased hippocampus and prefrontal cortex, which set up the relevance of the same pathway in amyloid-bearing tissue. After one week of intranasal treatment, microglial markers changed little. After four weeks, M2-like microglia increased significantly, while fibrillar β-amyloid burden did not yet shift in a measurable way which may indicate that inflammatory reprogramming may precede visible plaque improvement, and it also warns against demanding immediate amyloid readouts from interventions aimed first at the inflammatory machinery. When the investigators extended dosing to eight weeks, they found better working and spatial memory in Y-maze and Morris water maze tasks, reduced plaque burden, and improved neuronal signal. At later time points, the phenotype response evolved instead of remaining fixed in its earlier form. The authors connected that attenuation to immune tolerance in chronically stimulated microglia, an interpretation consistent with their scheme and with the observed loss of sustained anti-inflammatory suppression at later time points. Parallel molecular measurements supported the pathway argument: after four weeks, the nanozyme reduced TLR4 and NOX2 expression, lowered ROS, and damped downstream NF-κB-associated inflammatory signaling.

To summarize, Professor Haiming Luo and colleagues demonstrated that an intranasal nanozyme improved phenotype in a mouse model of Alzheimer’s disease. Their work linked in an elegant way the pathway control to a staged biological response, with early inflammatory modulation preceding later plaque reduction and cognitive improvement. Indeed, an important contribution here is the ordering of events. The data place microglial reprogramming early, amyloid and cognitive improvement later, and persistent pathway suppression somewhere in the middle of that sequence. That ordering reframes how anti-inflammatory nanomedicines might be evaluated. A therapy aimed at receptor-linked oxidant production may not need to reduce plaques first; it may instead act by changing the inflammatory setting in which plaques continue to injure tissue. That is a different design logic from the classical drug development which target direct anti-amyloid removal, and it has practical consequences for how dosing schedules, biomarkers, and response windows should be interpreted.

The reduced persistence of M2 polarization after prolonged treatment adds a temporal dimension to the response and suggests that microglial behavior changes as treatment continues. Repeated exposure to pathology can push them toward a tolerant state in which inflammatory readouts diminish but functional rescue may still emerge through cumulative changes already set in motion.   It hints that brain-directed antioxidant therapy may work through phase-specific biology, with an early window dominated by inflammatory reset and a later window dominated by tissue-level consequence. Any attempt to translate such a system would need to respect that temporal structure. Continuous dosing, intermittent dosing, or combination therapy with direct amyloid-targeting agents could perform very differently if microglial memory changes the tissue response after the first few weeks.

Intranasal delivery can give brain access without obvious long-term injury in the reported safety assays, the nanozyme retained stability under simulated nasal conditions, manganese ion release remained limited, and no obvious accumulation signal emerged in the brain over the studied interval. Those properties strengthen the translational relevance of the platform by addressing several early practical concerns surrounding brain-directed nanomaterials. More than that, the authors’ work highlights a design principle: a durable catalytic antioxidant can be useful because it can both removes oxidants and also interferes with a receptor-linked inflammatory circuit that helps define microglial identity in disease.

When chromatin loops must be rebuilt as cells leave mitosis, any interruption in cohesin activation can alter the contact architecture that genes encounter as transcription resumes. That problem sits near the center of current thinking about three-dimensional genome control, because loop extrusion is now treated as a major organizing process for subchromosomal structure, yet its kinetics inside mammalian cells have remained hard to define directly. Live-cell work had already implied short-lived loops, and biochemical work had established NIPBL as a key accessory factor for cohesin. Even so, a basic question stayed unsettled: does continuous NIPBL activity simply keep loops running at all loci, or does its importance depend on when a loop is being formed and what kind of chromatin the loop traverses?

A second uncertainty followed from transcription. Chromatin architecture has long been linked to gene control, but acute disruption of genome folding often changes expression far less than one might expect from the scale of structural disturbance. That mismatch left the field with an unsatisfying picture. Either many contacts were more dispensable than assumed, or only a particular subset of genes depended on a specific form of cohesin behavior that standard perturbations had not isolated cleanly. In a recent research paper published in Nature Genetics, Dr. Tessa Popay, Ami Pant,  Dr. Femke Munting, Dr. Melodi Tastemel, Dr. Morgan Black, Dr. Nicholas Haghani &led by  Professor Jesse Dixon from the Salk Institute of Biological Studies, developed an acute degron-based system for NIPBL depletion in human cells and used it to separate ongoing loop establishment from persistence of pre-existing chromatin contacts. They combined that perturbation with Hi-C, ChIP-seq, ChromHMM, and nascent-transcription profiling during both asynchronous growth and mitotic exit. The technical distinction from prior cohesin-removal studies is that this framework interrogates NIPBL-dependent loop extrusion dynamics directly rather than collapsing all cohesin-associated architecture at once. They also extended the same strategy to hiPSC-derived neurons and cardiomyocytes, allowing the local structural signature of NIPBL-sensitive genes to be compared across lineages.

The study was motivated as much by timing as by mechanism. Mitotic exit provides a natural reassembly window for genome structure, and that window makes it possible to separate loop formation from loop persistence in a living mammalian system. If a contact disappears only when NIPBL is removed during post-mitotic reorganization, but remains detectable when NIPBL is depleted in asynchronous cells, then the locus is revealing something important about maintenance logic rather than mere presence or absence of cohesin. The same reasoning extends to transcriptional activation after mitosis. Genes re-entering expression do not do so against a static chromatin background; they do so while local contact patterns are being rebuilt. The central problem, then, was not simply whether NIPBL affects chromatin loops or whether it affects RNA output. The deeper issue was whether a defined mode of loop extrusion produces a local genomic arrangement that certain genes require as they regain or sustain their active state.

The researchers first engineered hTERT RPE-1 cells for rapid dTAG-mediated depletion of NIPBL and paired that system with RAD21 depletion so they could distinguish loss of loop establishment from loss of cohesin itself. NIPBL removal began quickly, MAU2 fell with it, and RAD21 binding decreased across chromatin even though bulk chromatin-associated cohesin dropped only modestly. That difference is informative rather than incidental: a cell can retain chromatin-associated cohesin in a broad biochemical sense while still losing the locus-specific engagements that generate recognizable loops. Using Hi-C and RAD21-based classification, they defined 16,860 cohesin-dependent loops and found that these loops did not respond uniformly. Some declined sharply after NIPBL depletion, whereas another class persisted for hours. The mixed-dependency group became especially interesting because it weakened more at 24 hours than at 4 hours, implying that persistence reflected longevity of pre-existing structures rather than continued renewal. They then used mitotic exit as a direct test of formation logic. After synchronizing cells in mitosis, depleting NIPBL, and following genome reorganization through early G1, they saw that all loop classes depended much more strongly on NIPBL during reassembly than they did in asynchronous cells. The same mixed-dependency loops that could linger after acute depletion in cycling cells failed to establish properly during mitotic exit. It argues that persistence and establishment are separable properties in vivo, and it explains why an acute perturbation of NIPBL can expose loop lifetimes that would be invisible if one removed cohesin altogether.

The team pushed further by asking what marks the loops that endure. STAG1 enriched at the more NIPBL-dependent and persistent contacts, STAG2 showed the opposite pattern, and STAG1 knockout specifically weakened the mixed-dependency class after NIPBL depletion, whereas STAG2 knockout strengthened it. That pattern fits a residence-time model in which STAG1-containing cohesin remains chromatin-bound longer and can preserve selected contacts after new extrusion events have been curtailed. Chromatin context also tracked with loop behavior. Less dependent loops more often involved enhancer-rich regulatory elements, while the mixed-dependency class carried a stronger association with repressive chromatin and H3K27me3-flanked anchor environments. The locus mattered because loop stability was not being dictated by one universal timer; it was being shaped by subunit composition, chromatin state, and genomic setting together.

To connect structure with gene control, the researchers measured nascent transcription during mitotic exit by SLAM-seq. NIPBL depletion altered 549 genes in RPE-1 cells, with 457 reduced and 92 increased. Genes that failed to activate were enriched for programs tied to cell migration, cell shape, epithelial-mesenchymal transition, and KRAS signaling, and prolonged depletion shifted cell morphology toward a more epithelial-like state. Kinetic measurements sharpened the interpretation: reduced genes still began activation at roughly the normal early interval, yet they failed to build to full output after 60 minutes. That timing argues that NIPBL-dependent genome reorganization does not merely trigger the first burst of transcription; it supports continued productive activation as cells progress into G1. The spatial analysis matched that idea. Sensitive genes showed stronger contact with nearby super-enhancers and typical enhancers, along with weaker insulation across the transcription start site and stripe-like contact patterns extending through the promoter region. When NIPBL was removed, those local configurations weakened. In hiPSC-derived neurons and cardiomyocytes, the same design logic reappeared in a lineage-specific form: most dysregulated genes were cell-type-specific, yet the affected genes again displayed stronger enhancer proximity and characteristic promoter-centered contact structures.

 Professor Jesse Dixon and his team demonstrated that NIPBL-sensitive genes are embedded in a local contact geometry marked by close association with neighborhood super-enhancers, permissive communication across the transcription start site, and coordinated engagement among multiple regulatory elements. That arrangement gives cohesin dynamics a specific regulatory meaning. Rather than viewing loop extrusion as a broad architectural background process, the study places it inside the local operating logic of selected cell-identity genes. Genes of that class appear to need an active contact regime that can sustain transcriptional build-up, especially during post-mitotic reactivation. The study also links persistence to composition. STAG1 dependence and chromatin-state association are not decorative annotations on the loop classes. They provide a molecular explanation for why genome folding does not decay uniformly when NIPBL is removed. That matters for future work on cohesin regulation, because it means that the effect of perturbing a loader or ATPase regulator cannot be inferred simply from the effect of removing a core ring component. Distinct perturbations interrogate distinct layers of genome organization. Acute NIPBL depletion is especially useful in that respect, since it reveals how contact renewal shapes living chromatin without immediately erasing every cohesin-dependent feature.  The cross-lineage data extend the argument without overstating it. Neurons and cardiomyocytes did not merely recapitulate the RPE-1 response; they did so in a cell-type-specific transcriptional register, with different gene sets but a shared structural signature. That convergence supports a general design principle inside the scope of the experiments: NIPBL supports expression of lineage-defining genes by organizing a local promoter-enhancer neighborhood with unusually strong spatial coupling. The new study also provides a more exact way to think about why architectural perturbations often affect only a subset of genes. Sensitivity may depend less on promoter class alone and more on whether a gene relies on this particular contact topology to reach full transcriptional output.

Viral entry stalls whenever the envelope glycoprotein gp120 fails to engage the CD4 receptor with enough affinity to initiate the conformational cascade that ultimately drives membrane fusion. That interaction of gp120 with CD4 has been dissected repeatedly over the years, partly because it marks one of the earliest checkpoints in HIV infection where intervention is still possible. Much of the therapeutic antibody effort has therefore circled around this contact surface. The logic is fairly straightforward: if something can occupy or distort the gp120 regions responsible for CD4 recognition, the virus loses its foothold on the host cell. Broadly neutralizing antibodies have shown that this strategy can work, at least under certain conditions, since they recognize conserved regions of the envelope glycoprotein and reduce viral replication. However, HIV mutates relentlessly and even minor sequence shifts along exposed segments of gp120 can reshape the antigenic surface just enough for viral variants to slip past antibodies that once worked quite well.

Because of that mutational flexibility, combinations of antibodies have gradually become a common solution due to that different antibodies target different epitopes, so escape from one does not necessarily guarantee escape from the others. Several studies have supported this approach, both experimentally and clinically. The drawback, though, emerges once more than a few antibodies enter the mixture and manufacturing becomes complicated and regulatory evaluation also becomes less straightforward. Multispecific antibodies emerged from attempts to compress the same idea into a single molecular entity. In principle, one engineered antibody could bind multiple epitopes at once. Various formats have already been developed, including bi- and trispecific constructs. Even four binding arms might be incorporated within a conventional immunoglobulin scaffold. The difficulty, however, lies in the assembly. Multiple variable domains must fold and pair correctly, and that process does not always proceed cleanly. Mispairing, partial unfolding, or aggregation often creep into the picture. Another direction, somewhat unconventional at first glance, considers whether antigen-binding fragments might function outside a conventional antibody scaffold. Gold nanoparticle surfaces provide an unusual testing ground for that idea. Peptides attach readily through thiol groups and spread across the metallic interface. Earlier work introduced what are now called “goldbodies,” artificial antibody-like constructs generated by grafting complementarity-determining regions onto gold nanoparticles.

The difficult part, comes back to folding because antibody loops typically depend on the surrounding immunoglobulin framework to stabilize their shape. Remove that framework and the loops usually collapse into flexible, nonfunctional conformations. The goldization strategy proposes something slightly different. Multiple Au–S bonds restrict peptide motion across the nanoparticle surface, and those constraints appear to allow the binding loops to regain a configuration resembling their native state. The confined lowest energy fragment hypothesis attempts to rationalize this effect and antigen-binding fragments might not require a full antibody scaffold after all. One begins to imagine artificial antibody assemblies assembled directly on nanoparticles, with valence and composition extending well beyond what conventional immunoglobulins can realistically support.  A recent research paper published in ChemMedChem and conducted by Mr. Yiwei Sun, Ms. Rui Ni, Dr. Yuan-Yuan Liu, Dr. Haifang Wang, and led by Professor Aoneng Cao from the Institute of Nanochemistry and Nanobiology at Shanghai University, the researchers engineered artificial antibodies termed goldbodies by attaching antigen-binding peptide fragments from anti-gp120 nanobodies as well as the gp120-binding fragment of CD4 onto 3.6 nm gold nanoparticles. Each nanoparticle displayed multiple peptide loops capable of regaining functional conformation after Au–S conjugation. The researchers also constructed a mixed particle carrying four different binding fragments simultaneously, forming a candidate tetraspecific gp120-binding system. Binding assays confirmed strong and selective recognition of gp120 by these nanoparticle-based antibody mimics.

Briefly, the Shanghai University investigators designed four peptide fragments capable of recognizing HIV gp120 by extracting binding motifs from known protein–gp120 complexes. One peptide derived from a CD4 fragment that participates directly in gp120 recognition, while three additional peptides reproduced CDR3 loops from nanobodies A12, J3, and D7 that engage different epitopes on the viral envelope glycoprotein. Each fragment received sequence adjustments that allowed attachment to gold nanoparticles through terminal cysteine residues while maintaining structural flexibility required for refolding.  Each peptide exhibited a distinct density range in which binding responses to gp120 reached a maximum, roughly twenty peptides per particle for the CD4-derived fragment and lower densities for the nanobody loops.  The authors used circular dichroism spectroscopy to examine structural changes induced by nanoparticle attachment and found free peptide corresponding to the CD4 fragment adopted a disordered conformation in solution, but the conjugated form displayed spectral characteristics consistent with β-hairpin structure. This observation supports the notion that the gold surface constrains the peptide in a geometry resembling its original state within CD4. Loop-derived nanobody fragments lacked diagnostic spectral signatures distinguishing folded and disordered forms, so the investigators relied on binding assays as indirect evidence of functional refolding. They found all four goldbodies produced strong responses toward gp120 yet minimal interaction with the control proteins (bovine serum albumin and immunoglobulin G), while free peptides displayed no measurable binding. Interestingly, the authors prepared a mixed conjugate containing four peptide types in equal proportions, yielding a construct termed GbMix. Kinetic analysis using surface plasmon resonance revealed nanomolar to subnanomolar dissociation constants for the individual goldbodies and for the mixed particle. The GbMix construct displayed particularly strong affinity for gp120, a result that raises the possibility of cooperative binding interactions among fragments targeting distinct epitopes. The investigators acknowledged that such cooperation remains uncertain, since multivalent nanoparticle systems complicate quantitative affinity interpretation.

Antibody fragments normally rely on a large protein architecture to stabilize binding loops, on the other hand goldization replaces that framework with a nanoscale inorganic platform that imposes spatial restriction through surface bonding. This change in scaffold architecture produces several practical consequences. Conventional multispecific antibodies require careful pairing of heavy and light chains from different parental antibodies. Structural incompatibility often introduces misfolding or aggregation, especially as additional specificities enter the design. Gold nanoparticle scaffolds bypass these assembly problems because each peptide attaches independently. Antigen-binding fragments do not require cooperative folding with neighboring fragments to retain activity. Another implication involves valence. A conventional immunoglobulin contains four binding arms at most, while nanoparticle surfaces offer many potential attachment sites. Even a small particle near the size of a nanobody can accommodate multiple peptides, and larger particles could support dozens of binding fragments.  Viral mutation would then require simultaneous alterations across multiple antigenic regions to escape recognition.

The work of Professor Aoneng Cao and colleagues on artificial antibody systems based on nanoparticle scaffolds introduces a unique hybrid between nanotechnology and immunochemistry and instead of re-engineering entire antibody frameworks which is labor intensive process, researchers can explore combinations of short antigen-binding motifs assembled directly on nanoscale materials. If future work confirms multispecific viral neutralization, the new design principle could influence strategies for treating rapidly mutating pathogens as well as cancer antigens that exhibit heterogeneous surface expression.

The quick and precise response of neutrophils to infections or tissue injuries is essential for human survival. These specialized immune cells employ a range of mechanisms to contain microbial threats. One of the most remarkable is the formation of neutrophil extracellular traps (NETs), web-like structures composed of genomic DNA, histones, and antimicrobial proteins that immobilize pathogens in the extracellular space. While NETs play a pivotal role in host defense, recent research has shown that, under certain conditions, they can also contribute to disease. Inappropriately formed NETs have been linked to a range of disorders, including lupus, rheumatoid arthritis, cystic fibrosis, and even metastatic cancers. Therefore, several research groups are actively exploring pharmacological strategies to inhibit the inappropriate formation of NETs. At the core of NETs formation is neutrophil elastase (NE). This serine protease enters the nucleus and dismantles histones, initiating chromatin decondensation. This decondensed DNA is mixed with cytoplasmic proteins and then released from the neutrophil, forming the structural backbone of NETs. Given its central role, NE has naturally emerged as a potential therapeutic target. However, developing specific and well-tolerated inhibitors has proven to be a challenging task. Many compounds affect other proteases or require toxic concentrations, which can interfere with broader immune functions. Among the body’s natural countermeasures to NE is secretory leukocyte protease inhibitor (SLPI), a small protein found in mucosal surfaces and body fluids that can suppress NE activity and dampen inflammation more broadly. However, its potential as a therapy has long been undercut by an ironic flaw: NE can cleave SLPI at its amino terminus, disarming it before it can exert its full effect. This feedback vulnerability severely limits the protein’s stability in inflammatory environments.

A new research paper, published in Protein Expression and Purification and conducted by Felipe Gonzalez Contreras, Roxana Gutierrez Vidal, and Xristo Zarate from the University of Nuevo Leon and Cinvestav in Mexico, reports that researchers re-engineered SLPI into a more robust form. Rather than reinvent the protein entirely, they took a minimalist yet strategic approach—substituting two amino acids at the N-terminal site most prone to NE cleavage. Their aim wasn’t just to protect SLPI from degradation but to preserve its function at lower, pharmacologically relevant doses. In doing so, they hoped to restore SLPI’s original promise—not as a blunt inhibitor, but as a precise modulator of inflammation during the critical early stages of immune activation. The authors began with a very targeted question: could they modify SLPI just enough to shield it from enzymatic inactivation without undermining its function? They focused on amino acids serine-15 and alanine-16, both of which are recognized as cleavage points for neutrophil elastase. Replacing them with glycine seemed, at least theoretically, to be a minor structural adjustment. But in proteins as compact and functionally sensitive as SLPI, even subtle edits can have unintended ripple effects. To test this SLPI variant (rSLPIv), they chose E. coli SHuffle T7 for expression—a system known for its capacity to form disulfide bonds in the cytoplasm, which is critical for a cysteine-rich protein like SLPI. They also opted to add an SmbP fusion tag, which wasn’t just for purification—it also helped with solubility, a notoriously problematic issue in prokaryotic expression. After a round of optimization, the results were solid. Electrophoretic analysis revealed a clean band and mass spectrometry confirmed the expected molecular weight. But all of this was, in essence, a preamble. The real test came when they exposed freshly isolated human neutrophils to PMA, a known trigger of NETosis that can lead to the formation of large nuclear areas (>800 µm²), and then added rSLPIv at different concentrations. What stood out immediately was the potency: 10 nM was sufficient to reduce NETs formation by approximately 30%. That’s a meaningful reduction—especially given that wild-type SLPI often requires micromolar dosing to achieve a comparable effect. More surprisingly, the suppression held over several hours. Such durability is rare in this field. Following this, the authors used confocal microscopy, where they stained the DNA and looked at nuclear morphology, measuring the spread of the nuclei. As expected, they found that PMA alone caused the nuclei to swell and unravel—hallmarks of chromatin decondensation. However, when treated with rSLPIv, particularly at a concentration of 50 nM, the nuclei remained tightly packed and much more compact. Quantitative image analysis supported this observation: over half of the cells (69%) displayed a smaller nuclear area, comparable to that of neutrophils not exposed to PMA, with sizes below 800 µm².

The scope of this work reaches far beyond the mechanistic details of NETs biology. While NETosis was once thought of as an isolated immune event, it has since been implicated in a staggering variety of pathological contexts—autoimmune diseases like lupus and rheumatoid arthritis, of course, but also sepsis, cancer metastasis, and most recently, the thromboinflammatory damage seen in severe COVID-19 cases. Despite this growing body of evidence, therapeutic strategies to specifically inhibit NETs formation remain frustratingly limited. At present, DNase I is the only FDA-approved agent that targets NETs, and even then, it does so only after they’ve formed. By degrading the DNA backbone, it clears the structural web. Still, it leaves behind enzymatically active proteases that can exacerbate tissue damage—hardly a perfect solution. That’s where rSLPIv offers a compelling alternative. Rather than cleaning up after the fact, it prevents NETs from forming in the first place—intervening at the level of chromatin decondensation upstream of DNA extrusion. Mechanistically, this is a far cleaner point of control. From a clinical standpoint, it may also be safer as it avoids triggering a secondary wave of inflammatory damage caused by the release of proteases, such as neutrophil elastase.

Equally worth noting is the platform used to produce the molecule. Recombinant expression of human proteins in E. coli is often viewed as a compromise, especially for proteins that are small, rich in disulfide bonds, or structurally delicate—rSLPIv ticks all three boxes. However, in this case, Dr. Xristo Zarate and colleagues successfully produced a high-purity, soluble variant using a relatively straightforward bacterial system, which highlights the elegance of their construct design. This has real implications for scalability and cost—two factors that routinely derail biologics in early translational stages. Moreover, minimalistic, structure-informed engineering can breathe new life into endogenous proteins that might otherwise be dismissed as therapeutically impractical. With a focus on N-terminal cleavage, they successfully enhanced molecular durability while preserving SLPI’s innate regulatory function.

Dr. Xristo Zarate, Principal Investigator, told Medicine Innovates: “This project is a clear demonstration of how biotechnology and protein engineering can converge to solve complex problems in immune regulation. It also reflects the dedication of young scientists like Felipe, whose work is shaping the next generation of therapeutic proteins“

There has been significant interest in the development of messenger RNA (mRNA)-based treatments lately which are uniquely is able to directly instruct cells to produce specific proteins which makes mRNA an attractive candidate for personalized medicine because it allows for tailored therapies that can be adjusted in dosage and frequency to meet individual patient needs. Despite these advantages, the clinical application of mRNA therapies still faces significant challenges. One of the primary hurdles is the inherent instability of mRNA molecules, because they are sensitive to rapid degradation by ribonucleases (RNases) present in extracellular fluids and biological environments. Another critical challenge is the efficient delivery of mRNA into the cells because naked mRNA molecules are too large and negatively charged, which make them unable to internalize. Moreover, even when mRNA enters the cells through endocytosis, it often remains trapped within endosomes, where it can be degraded before reaching the cytoplasm. For the effective mRNA therapies drug development, they must overcome these limitations. Although various delivery systems have been proposed to address these issues such as lipid-based and polymer-based carriers which showed promise in protecting mRNA from degradation and facilitating its cellular uptake. However, these systems often encounter limitations in terms of stability, efficiency of endosomal escape, and potential cytotoxicity. To this end, Professor Hyun-Ouk Kim at Kangwon National University and conducted by HakSeon Kim, Yu-Rim Ahn, Minse Kim, Jaewon Choi, SoJin Shin developed a novel mRNA delivery system termed “ChargeSomes which improved the stability and delivery efficiency of mRNA through the use of charge-complementary polymersomes. The new study is now published in the Pharmaceutics Journal.

The first step the researchers synthesized the charge-complementary polymers methoxy polyethylene glycol-block-poly-L-lysine (mPEG-b-PLL) and methoxy polyethylene glycol-block-poly-L-lysine-succinic anhydride (mPEG-b-PLL-SA) and then confirmed the successful synthesis of these copolymers using nuclear magnetic resonance and Fourier-transform infrared spectroscopy. The physicochemical properties of ChargeSomes were then analyzed using dynamic light scattering and transmission electron microscopy which demonstrated that ChargeSomes formed stable, spherical nanoparticles with a bilayer structure. These nanoparticles varied in size depending on the ratio of mPEG-b-PLL to mPEG-b-PLL-SA, with a 9:1 ratio showing optimal characteristics for mRNA delivery. Afterward, the authors assessed the stability of ChargeSomes, and they monitored the size distribution in phosphate-buffered saline at pH 7.4 over six weeks using DLS and they showed that ChargeSomes maintained consistent stability at neutral pH, indicating their robustness under physiological conditions. Furthermore, to evaluate the pH sensitivity, ChargeSomes were exposed to an acidic environment, simulating endosomal conditions. The nanoparticles exhibited significant size changes between 3 and 8 hours, confirming their pH-responsive behavior and capacity to release mRNA in acidic environments, essential for effective endosomal escape. The team also evaluated the cytotoxicity of ChargeSomes using RAW 264.7 cells and showed that ChargeSomes has minimal cytotoxicity across various concentrations and ratios of mPEG-b-PLL to mPEG-b-PLL-SA. Specifically, a 7:3 ratio showed high cell viability, confirming the safety of ChargeSomes for therapeutic applications. According to the authors, at a concentration of 0.21 mM, ChargeSomes exhibited optimal characteristics for further in vitro experiments, maintaining cell viability comparable to that of lipofectamine, a commonly used transfection reagent. Moreover, the researchers examined the efficiency of cellular uptake and endosomal escape of ChargeSomes using confocal laser-scanning microscopy (CLSM) and flow cytometry. Ovalbumin conjugated with fluorescein isothiocyanate (FITC–OVA) served as a model antigen to track cell uptake. The author’s findings indicated that OVA–FITC-encapsulated ChargeSomes showed superior cellular uptake compared to OVA–FITC alone, as evidenced by increased green fluorescence intensity in RAW 264.7 cells. Flow cytometry further corroborated these findings, with higher fluorescence levels in cells treated with ChargeSomes. To analyze endosomal escape, the authors incubated the cells with ChargeSomes over a temporal gradient and their studies demonstrated rapid transition from cell uptake to endosomal escape within 6 hours highlights the efficiency of ChargeSomes in delivering mRNA.

The researchers further tested the transfection efficiency of ChargeSomes using Enhanced Green Fluorescent Protein (EGFP) mRNA and confirmed the encapsulation and stability of EGFP mRNA within ChargeSomes, even in the presence of PBS, RNase, and fetal bovine serum. In contrast, cells treated with naked mRNA exhibited no EGFP expression, suggesting degradation or failed internalization of unencapsulated mRNA. Quantitative evaluation using flow cytometry revealed that mRNA delivery via ChargeSomes significantly improved EGFP expression efficiency compared to naked mRNA. The results indicated that ChargeSomes facilitated effective endosomal escape and cytoplasmic delivery of mRNA, with the 9:1 ratio showing the highest transfection efficiency due to its optimal physicochemical properties.

One of the major contributions of the new study is the development of a delivery system that significantly enhances the stability and protection of mRNA molecules. ChargeSomes shield mRNA from degradation by RNases and the use of charge-complementary polymers ensures that the mRNA is securely encapsulated, which is a substantial improvement over traditional delivery methods that often fail to provide adequate protection. In conclusion, Professor Hyun-Ouk Kim and his team demonstrated that ChargeSomes is a safe and efficient mRNA delivery technology that can enhance cellular uptake and promote effective endosomal escape. Additionally, the practical implications of work of Professor Hyun-Ouk Kim and colleagues extend to the development of non-viral gene therapy as well as mRNA vaccines.  Future studies should further confirm the in vivo efficacy of ChargeSomes in animal models and eventually in human trials. The versatility of the ChargeSome platform allows for the potential development of delivery systems for other types of nucleic acids, such as small interfering RNA (siRNA) or DNA which will broaden the scope of gene therapy applications.

The human brain, shielded by the highly selective blood-brain barrier (BBB), remains one of the most difficult organs to target pharmacologically. Nowhere is this challenge more consequential than in diseases where neuroinflammation plays a central role—such as cancer cachexia, a devastating condition marked by severe weight loss, muscle atrophy, and metabolic dysfunction. Among the key brain regions implicated in this syndrome is the hypothalamus, the central hub for energy homeostasis and appetite regulation. Inflammation within this region disrupts critical signaling networks, creating a self-perpetuating loop of anorexia and wasting that is notoriously resistant to treatment. At the heart of this neuroinflammatory process are microglia—the brain’s resident immune cells—which respond to systemic inflammatory cues by releasing cytokines that impair hypothalamic function. Yet despite their centrality to disease progression, microglia have remained largely inaccessible to systemic drug therapies due to the impermeability of the BBB and the lack of cell-specific delivery technologies. Current treatment strategies for cancer cachexia and related inflammatory brain conditions are severely limited, in large part because systemic drugs either fail to reach the brain or affect non-target cells indiscriminately, leading to suboptimal efficacy and potential toxicity. Anti-inflammatory agents such as IRAK4 inhibitors, while mechanistically promising, are typically unable to cross the BBB and accumulate in sufficient concentrations in target areas like the hypothalamus. Moreover, even if a small fraction reaches the central nervous system, the lack of cellular specificity means that therapeutic agents may diffuse broadly across neural and glial populations, blunting their intended effects and risking unintended side effects.

New research paper published in Advaned Healthcare Materials and conducted by Yoon Tae Goo, Vladislav Grigoriev, Tetiana Korzun, Kongbrailatpam Shitaljit Sharma, Prem Singh, Professor Olena R. Taratula, Dr. Daniel L. Marks, Professor Oleh Taratula from the Oregon State University, researchers set out to rethink how drugs could be delivered to the brain—not just to the organ itself, but to the specific cell populations driving disease. Their approach is grounded in two fundamental insights: first, that BBB penetration requires specialized molecular tools; and second, that once inside the brain, drugs must be guided with surgical precision to the cells most responsible for inflammation. By developing a nanocarrier system decorated with two distinct peptides—one to enable transit across the BBB and the other to hone in on activated microglia—they aimed to achieve a level of precision previously unattainable with conventional drug delivery methods. Their study represents not just a technical feat in nanomedicine, but an attempt to bridge a critical therapeutic gap in the treatment of brain-centered metabolic diseases like cancer cachexia.

The researchers began by engineering nanoparticles composed of PEG-PCL polymers, loading them with the IRAK4 inhibitor zimlovisertib (ZLV), a drug known for its potent anti-inflammatory properties but hindered by poor solubility and inability to cross the blood-brain barrier. By conjugating these nanoparticles with two carefully chosen peptides—CGN to facilitate passage across the BBB, and MG to selectively bind pro-inflammatory microglia—the authors created what they hoped would function as a precision-guided therapy for hypothalamic inflammation. Initial in vitro tests employed a co-culture model mimicking the BBB. Brain endothelial cells were grown atop a membrane, beneath which lay microglial cells pre-activated with inflammatory stimuli. When the dual-functionalized nanocarriers were introduced, they successfully crossed the endothelial layer and were taken up preferentially by activated microglia, far more than by anti-inflammatory or quiescent cells. This was a pivotal moment—one that confirmed the peptides were doing their jobs. The CGN peptide enabled traversal of the cellular barrier, and the MG peptide ensured that the payload was delivered exactly where it was needed. Next came the in vivo experiments. In a mouse model of acute neuroinflammation induced by lipopolysaccharide (LPS), systemic injection of the nanocarriers led to pronounced accumulation in the hypothalamus, where inflammation is known to be concentrated during sickness behavior. Notably, when the brains were examined, fluorescence imaging showed that the nanoparticles had co-localized almost entirely with microglial cells, and not with other neural cell types. But the most compelling evidence came from the animals themselves: those treated with the dual-targeted nanocarriers regained appetite, maintained body weight, and showed dramatically reduced levels of inflammatory cytokines in their hypothalami. The findings were even more profound in a mouse model of cancer-associated cachexia. Animals bearing pancreatic tumors typically show severe reductions in food intake and muscle mass. However, when treated with the ZLV-loaded nanocarriers, these mice not only ate more and lost less weight, but their hypothalamic tissue showed lower expression of key inflammatory markers like TNF-α and LCN2.

The significance of this study lies not only in what it accomplished but in the door it quietly opened for the future of brain-targeted therapeutics. For decades, the blood-brain barrier has been a brick wall between medical science and effective neurological treatments—especially for conditions like cancer cachexia, where systemic inflammation hijacks the brain’s appetite centers, and no approved therapy addresses the root cause. By engineering a delivery system that can both cross this wall and navigate the cellular complexity of the brain to locate activated microglia, the researchers demonstrated that the impossible might simply require better tools, not resignation. This work marks a pivotal departure from traditional pharmacology’s broad-stroke strategies. Instead of flooding the system with a drug and hoping a fraction reaches the brain, the approach here is methodical, precise, and respectful of the brain’s biological nuance. The dual-targeting mechanism—using one peptide to breach the barrier and another to locate microglia—offers a level of control that could shift how we think about CNS treatment paradigms. It’s not just about getting drugs into the brain anymore; it’s about directing them with near-surgical accuracy once they’re there. Equally important are the clinical implications. Cachexia is one of the most devastating complications in late-stage cancer patients, robbing them of strength, appetite, and dignity. That these nanocarriers restored food intake and preserved muscle mass in a well-established mouse model signals more than proof-of-concept—it offers a tangible step toward improving patient quality of life. Beyond cachexia, this method could be adapted for neurodegenerative conditions where microglial overactivation plays a central role—such as Alzheimer’s disease, Parkinson’s, or multiple sclerosis. The platform’s modularity allows for swapping out payloads and even retargeting peptides, making it a versatile vehicle in the neuroscience toolkit.

Cancer immunotherapy changed the treatment landscape by making durable tumor control possible through activation of the host immune system rather than direct cytotoxic attack alone. Among the major advances in oncology, immune checkpoint blockade is particularly attractive because antibodies targeting inhibitory pathways such as PD-1, PD-L1, and CTLA-4 showed that the “immune brake” of antitumor immunity could be released in a clinically meaningful way in at least a subset of patients. They also made clear that the immune system is not a secondary participant in cancer therapy, but in many settings a decisive determinant of whether tumor control can be sustained, extended to disseminated disease, or lost altogether. Checkpoint-based immunotherapy produces excellent clinical benefit in some patients but much weaker effects (70%~ 80%) in many others, and that uneven performance has remained one of the problems/grand challenges in the field. Several theories tried to explain this including T-cell exhaustion, insufficient neoantigen availability, and strongly immunosuppressive tumor microenvironments. Each of those factors carries weight, however, none fully resolves the basic question of why releasing antitumor inhibitory signaling can generate deep clinical responses in some tumors while producing only modest benefit in others. The issue becomes especially important in solid tumors, where immune priming, antigen presentation, and local suppression rarely evolve in a coordinated way.

A recurring difficulty is that successful immunotherapy requires more than the presence of T cells in or around a tumor. It depends on the presence of T cells that have actually acquired the capacity to recognize tumor-associated features and respond productively after stimulation. When that population is limited, the therapeutic value of checkpoint release or immune co-stimulation is limited from the outset.   The authors^[1] argue that many antigen-specific T cells remain functionally ineffective because they have not undergone adequate education through dendritic-cell presentation of tumor-derived material. A more effective strategy may require generating a larger supply of immunogenic tumor debris first, so that new tumor-recognizing cytolytic T cells can be primed before immunotherapy is expected to exert its full effect.

That reasoning creates a strong case for combining immunotherapy with a local treatment capable of producing both tumor destruction and immune-relevant neoantigen release. Phototherapy is attractive in that regard because it can damage cancer cells directly while also altering the inflammatory and antigenic environment within the tumor. In a recent research paper published in ACS Nano,^[1] Dr. Munusamy Shanmugam, Dr. Chi-Shiun Chiang, and Professor Kuo Chu Hwang from the National Tsing Hua University, Taiwan, developed PEG-folate-functionalized LaB₆ nanoparticles that absorb across NIR-I through NIR-IV and support wavelength-resolved phototherapy within one materials platform. They paired those nanoparticles with 2240 nm irradiation and anti-OX40 to create a local-to-systemic treatment strategy that couples tumor photodynamic destruction to immune co-stimulation. What is new here is the use of NIR-IV photodynamic priming to generate in situ whole-tumor vaccine material and convert a weak anti-OX40 response into strong control of remote and metastatic melanoma. They also framed the mechanism with a “blind T cells” model (see Scheme 1) that links poor immunotherapy performance to an upstream shortage of newly primed tumor-recognizing cytolytic T cells.

The research team first built the therapeutic system around LaB₆ nanoparticles modified with PEG-folate, and the choice carried two immediate experimental consequences: prolonged circulation after intravenous dosing and stronger uptake by folate-receptor-expressing melanoma cells. The investigators measured a blood half-life of about 20 hours for the PEG-folate particles, compared with 9 hours for unmodified LaB₆, and they detected higher tumor accumulation at 24 hours, which is why they fixed that time point for irradiation. That scheduling detail mattered because earlier irradiation would have obscured the effect of tumor enrichment of the nanomaterial. The authors then used the same nanoparticle platform to compare 808, 1064, 1550, and 2240 nm NIR light photo-excitation. They observed singlet oxygen generation at 1064 nm, whereas 1550 and 2240 nm produced strong hydroxyl-radical signals, even under hypoxic conditions, far above the values measured at 1064 and 808 nm. This distinction is relevant because hypoxia often weakens classical photodynamic strategies. Here, the longer-wavelength channels did not depend on the same oxygen chemistry, and that gave the NIR-III and NIR-IV conditions a different biological footing from the start. The study examined cell killing under those irradiation modes and found that ROS-producing conditions depressed melanoma viability more strongly than 808 nm treatment, which behaved mainly as photothermal heating. The comparison also brought out an instructive trade-off: 808 and 1550 nm produced larger temperature rises, but the deepest antitumor gains did not track peak heating alone.

The investigators carried that logic into immunogenic cell death. They observed that photodynamic conditions drove tumor death mainly through necrosis-dominant patterns, while 808 nm treatment yielded a more mixed necrotic-apoptotic profile. They then measured CRT exposure, HMGB1 release, and ATP release and found all three increased after photoirradiation, with the 2240 nm condition producing the highest DAMP levels. The research group also measured light transmission through tissue and recorded transmission reached 46% at 2240 nm, compared with 26% at 808 nm. That tissue-penetration gradient gives a plausible physical reason why the longest wavelength generated the strongest immunogenic output in the tumor model: more usable light survived tissue passage, so more nanoparticles could participate in chemistry deeper in the lesion.

The mouse studies tied these physical and cellular results to antitumor behavior. The researchers implanted primary and remote B16BL6 tumors and irradiated only the primary site. Without anti-OX40, all nanoparticle-plus-light groups slowed primary growth, but remote control stayed modest. After adding anti-OX40, remote suppression improved sharply, with the strongest effect at 2240 nm; median half-lifespan extended from 21 days to 83 days. The study also examined lung metastasis qualitatively and found visible metastatic nodules essentially absent in the 1550 and 2240 nm combination groups. When the investigators repeated key experiments in immune-deficient SCID mice, the therapeutic benefit dropped to roughly half of what they observed in immunocompetent animals. That loss is telling, because it argues that direct tumor phototoxicity was not carrying the whole treatment effect. The boosted outcome depended heavily on intact adaptive immunity.

The authors measured immune profiling of serum TNF-α, IFN-γ, IL-2, and IL-12 and found strong increases in the nanoparticle-plus-light-plus-anti-OX40 groups, especially under 1550 and 2240 nm irradiation. They also recorded stronger dendritic-cell maturation and larger populations and enhanced IFN-g  production activity of CD8⁺ T cells, while the paper’s discussion attributes the combined therapy to simultaneous expansion of antitumor compartments and suppression of Treg and M2-type macrophage activity. Anti-OX40 alone could move the system somewhat, but once the photodynamic treatment generated a much larger supply of immunogenic tumor neoantigens, the agonist operated in a very different immune setting. Professor Kuo Chu Hwang and colleagues demonstrated that many less effective immunotherapy responses may be interpreted too narrowly when viewed mainly through checkpoint biology. Their data push attention upstream, toward antigen availability, dendritic-cell maturation, inflammatory cytokines, and the generation of freshly primed tumor-recognizing cytolytic T cells first, instead of removing the “immune brake” of the existing, but “blind” CD8⁺ T cells.

Long-wavelength photomedicine often draws attention because of penetration depth, but the new work links penetration to a specific immunological consequence: deeper light delivery produces more extensive, more immunogenic tumor destruction, which then changes how well an agonist immunotherapy can work at distant, untreated sites. The authors went beyond showing that 2240 nm light can damage a tumor and built a case that wavelength choice can alter the quality of the immune conversion triggered by local treatment. If that principle survives in larger and more heterogeneous tumor models, it could influence how photodynamic systems are designed when systemic immune cooperation is the real therapeutic goal. The study gives timing and sequence a more mechanistic role than they often receive in combination-therapy design. Anti-OX40 was not simply added to phototherapy; it was placed into a setting where tumor killing had already generated antigenic debris and inflammatory signals. That order is important because co-stimulation without sufficient antigen priming can only do so much. One can imagine this logic informing combinations with checkpoint inhibitors, cytokine agonists, radiation, chemotherapy, or other cell-killing modalities, though any such extension would need careful testing because the balance among antigen release, suppressive myeloid cells, and T-cell priming is unlikely to remain constant across tumor types.  

By using one nanoparticle family across four near-infrared windows, the authors reduced a common source of ambiguity in comparative phototherapy papers. The wavelength-dependent differences can be read with more confidence because the photosensitizing platform stayed materially consistent. That makes the ranking of 2240 nm above 1550 nm, and both above 1064 and 808 nm in this melanoma system, more persuasive than a comparison built from unrelated agents. Whether the same ordering will persist in thicker tumors, other anatomical settings, or clinically practical light-delivery conditions remains to be determined, but the central point is clear: immunotherapy becomes more effective when local tumor killing first expands the pool of tumor-recognizing T cells.

   Overall, the “blind T cells” concept can be illustrated in the Scheme I.  Large majority of existing CD8⁺ T cells in cancer patients are actually “blind”, meaning cannot recognize tumor cells.  Under such a condition, removing the “immune brake” by using immunotherapy agents will not improve the cancer cell killing efficacy, but leads to various autoimmune adverse effects.  The “blind T cells” model suggests shifting the paradigm of cancer treatments to creation of new tumor-recognizing cytolytic T cells before removal of the “immune brake” using immunotherapy agents.   Clinically, medical doctors in Taipei Veterans General Hospital in Taiwan observed that  among 107 patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), the mediam number of patients treated with combined chemotherapy and immunotherapy has a longer overall survival of 20 months than 16 months from those treated with immunotherapy alone.^[2]   Medical doctors in Chang Gung Memorial Hospital at Linkou, Taiwan, also observed that among 137 human patients with liver cancer at late stage B or C hepatocellular carcinoma, the two year overall survival rate for patients treated with combined proton radiotherapy and immunotherapy is 77%, which is significantly higher than 42.7% observed from patients treated with proton-Tyrosine Kinase Inhibitor group and 52.7% from patients treated with proton radiotherapy alone.^[3]  These observations in clinical human cancer patients are supportive data for the validity of the “blind T cells” model.  The “blind T cells” model proposes a new strategy to overcome the grand challenge of ineffectiveness of immunotherapies by shifting the paradigm of cancer treatments to generation of a massive number of newly created, tumor-recognizing cytotoxic T cells before immunotherapy is administered, instead of simple release of “immune brake” by immunotherapy alone.

Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant forms of brain cancer, with a five-year survival rate stubbornly below 10%. Despite decades of genomic research and an explosion of targeted therapy development, meaningful improvements in clinical outcomes have remained elusive. Part of the reason lies in GBM’s bewildering complexity—not just its mutational diversity, but the profound variability in how individual tumor cells behave, adapt, and survive under therapeutic pressure. Standard classification based on molecular subtypes, such as mesenchymal, classical, and proneural, has offered some clarity, but it has failed to translate into reliably effective, subtype-specific interventions. A growing body of evidence suggests that this is not merely a problem of which genes are mutated or expressed, but how the regulatory logic of those genes is organized in three-dimensional (3D) nuclear space. Traditional genomic studies view gene regulation as a linear process: enhancers activate nearby promoters, genes are transcribed, and cell identity is maintained or altered. However, this one-dimensional framework overlooks the physical reality of the genome folded inside the nucleus. Increasingly, it has become clear that enhancer-promoter communication is spatially orchestrated, not randomly or passively, but through complex networks of chromatin looping that bring regulatory elements into proximity, sometimes over hundreds of kilobases. This spatial architecture is not just a passive scaffold—it actively contributes to which genes are turned on, how strongly, and in what combinations.

To this account, new research paper published in Molecular Cell Journal and led by Professor Howard Fine and Associate Professor Effie Apostolou from the Weill Cornell Medicine and conducted by Sarah Breves, Dafne Campigli Di Giammartino, James Nicholson, Stefano Cirigliano, Syed Raza Mahmood, Uk Jin Lee, Alexander Martinez-Fundichely, Johannes Jungverdorben, Richa Singhania, Sandy Rajkumar, Raphael Kirou, Lorenz Studer, Ekta Khurana, and Alexander Polyzos investigated whether glioblastoma’s malignancy could be better understood through its 3D genomic organization. Specifically, they wanted to identify whether densely interconnected enhancer-promoter networks—termed “hyperconnected 3D regulatory hubs”—play a foundational role in driving the tumor’s transcriptional programs. They hypothesized that such hubs might serve as central organizing units that coordinate the expression of key oncogenes and possibly less-studied genes drawn into oncogenic networks through spatial proximity. Indeed, what makes this line of inquiry so compelling is its potential to explain phenomena that linear genomics cannot. For example, why do certain genes without recurrent mutations or obvious epigenetic marks still exhibit high expression in GBM? How can different tumors, each with distinct mutation profiles, converge on similar malignant phenotypes? And why do targeted therapies often yield only transient benefits? The answer may lie in the existence of 3D hubs that integrate and amplify oncogenic signals across gene networks, creating a system that is not only robust but remarkably adaptable.

To explore how spatial genome organization contributes to glioblastoma’s malignant behavior, the Weill Cornell Medicine researchers began by mapping enhancer-promoter interactions in four patient-derived glioblastoma stem cell (GSC) lines using H3K27ac HiChIP. This method allowed them to trace thousands of loops between active enhancers and promoters, revealing a dense web of regulatory interactions. These maps weren’t uniform; they varied across patients, aligning with known molecular subtypes like mesenchymal and classical, yet also exposing previously hidden layers of regulation. Importantly, the team identified specific genomic regions with exceptionally high connectivity—so-called “3D hubs”—that clustered numerous enhancers and promoters into regulatory centers. What made these hubs intriguing was that genes residing within them were not just active; they were highly co-regulated and disproportionately linked to oncogenic pathways. Using single-cell RNA sequencing, the researchers confirmed that genes within the same hub exhibited remarkably synchronized expression patterns across individual tumor cells—suggesting these hubs functioned as coordinated transcriptional units rather than coincidental groupings. To determine whether these structures had causal influence, not just correlation, the team employed CRISPR interference (CRISPRi) to silence specific hubs. In one experiment, they targeted a hub that included the proto-oncogene JUN, observing that not only did JUN expression fall, but so did several other genes connected to the same hub. These weren’t random transcriptional ripples; the entire local network dimmed, underscoring the hub’s role in maintaining coordinated gene activity.

The authors afterward turned their attention to a previously uncharacterized hub near GOLIM4—a region not traditionally associated with GBM. When they silenced this hub using a stable, inducible CRISPRi system, they found that all six connected genes were downregulated, and the GSCs shifted their transcriptional identity. This wasn’t just a subtle reprogramming; the cells adopted different states when grown in 3D brain organoid models, showing changes in clonogenic capacity and expression of genes tied to aggressive tumor behavior. What’s more, targeting single genes within the hub did not reproduce the full effect, suggesting that the hub’s function stemmed from its interconnected nature rather than any single node. Looking beyond glioblastoma, the researchers extended their analysis to 88 samples across 16 cancer types. They discovered that hyperconnected 3D hubs are not a GBM-specific anomaly but a recurring theme in tumor biology. Some were cancer-type-specific, while others spanned multiple malignancies, converging on universal oncogenic pathways like MYC and p53 signaling.

In conclusion, the study by Professor Howard Fine and Associate Professor Effie Apostolou reframes how we understand gene regulation in glioblastoma by demonstrating that the tumor’s aggressive behavior is orchestrated not just by linear genetic changes, but by complex three-dimensional structures in the nucleus. These hyperconnected 3D hubs act as regulatory epicenters, coordinating the expression of gene networks that define malignant identity. What makes this discovery especially significant is its ability to bridge a long-standing gap in cancer biology—explaining why tumors with vastly different mutations often exhibit remarkably similar behaviors.

We believe the implications are wide-reaching. First, it suggests that spatial genome architecture is a critical component of the oncogenesis regulatory logic. This perspective shifts the focus away from isolated genes and toward higher-order structures that govern entire transcriptional programs. Therapeutically, it opens the door to targeting regulatory hubs instead of individual genes—an approach that could simultaneously disrupt multiple oncogenic drivers and their supporting networks. Another key takeaway is the discovery that many of these hubs do not rely on structural mutations to form. This means that the epigenetic machinery, including transcription factors and chromatin organizers, plays a larger-than-expected role in shaping malignant phenotypes. Because such factors are more dynamic and potentially reversible, they offer more accessible intervention points than fixed genetic lesions. In fact, the study identified transcription factors enriched in hub-associated regions whose elevated expression correlates with poor prognosis across multiple cancers.  Moreover, the new finding that hub silencing can lead to coordinated transcriptional collapse—not just a downregulation of one gene, but a destabilization of an entire network. This has profound implications for designing therapies that aim to overcome the redundancy and adaptability that make glioblastoma so resistant to treatment. The idea that disrupting a single hub can alter cellular states and reduce clonogenic potential redefines how we might approach tumor targeting in the future.  Lastly, the recurrence of similar 3D hubs across diverse cancer types hints at a unifying principle behind oncogenic regulation—one that transcends tissue of origin. If validated further, this could become a cornerstone in developing universal, architecture-based cancer therapies. Rather than chasing every mutation, we might instead dismantle the regulatory frameworks that allow cancer cells to act in concert, survive stress, and evade control. This study lays the foundation for that possibility, with a clarity and precision that could reshape both diagnostics and therapeutic strategies in cancer biology.

Among the most difficult targets in drug discovery are protein–protein interactions (PPIs). PPIs are essential extra- and intracellular processes that are often implicated in disease progression such as cancer, autoimmune disorders, cardiovascular diseases, inflammatory and neurodegenerative conditions. However, the very nature of PPIs—characterized by large, shallow, and dynamic binding surfaces—renders them technically challenging to disrupt with conventional small molecules. Monoclonal antibodies represent the most promising strategy in this therapeutic space, but their large size, poor permeability, low tissue penetration, and systemic clearance remain a significant challenge. This is where AdaptBio Therapeutics’ proprietary ADAPT platform (short for Adaptive Design of Antibody Paratopes into Therapeutics) originally developed by Professor Stéphane Roche at the Florida Atlantic University comes in, bridging the gap between small-molecule and antibody drugs to create a new generation of peptide therapeutics.

One major difficulty in designing such molecules is to ensure scaffold stability and proper folding since peptides often lack the structural rigidity needed to effectively mimic antibodies. Indeed, most PPI inhibitors derived from antibodies fail to maintain their active conformation when removed from their native context. Another fundamental challenge is that many PPI interfaces, such as PD1/PDL1, lack well-defined binding pockets which adds difficulty to the design of high-affinity inhibitors. Recent studies by the Roche group started to unveil the structural principles that govern the stability and folding of the complementarity-determining region H3s (CDR-H3s) found in antibodies.(1) In comparison to all other CDRs, CDR-H3 loops are known to possess the largest variability of sequence, topology, and length needed to maximize antibodies’ binding affinity and specificity. Inspired by these highly adaptable CDR-H3 loops, ADAPTins are engineered β-hairpin peptide scaffolds that retain the specificity of antibodies while overcoming their pharmacokinetic limitations. These peptides offer a game-changing approach to disrupting PPIs, enabling targeted interventions in oncology, immunology, and beyond.

“As we continue to unlock the full potential of our ADAPTin platform, our goal is to demonstrate the disruptive nature of our technology, because we have a new valuable tool in hand to streamline the synthesis of peptides never seen before” Stéphane Roche, PhD, Founder and Chief Executive Officer of AdaptBio Therapeutics.

In a recent study, the team of researchers at Florida Atlantic demonstrated that ADAPTins can effectively inhibit the PD1/PDL1 immune checkpoint interaction, a key target in cancer immunotherapy. Unlike traditional antibodies, which require intravenous administration and have long half-lives, ADAPTins are designed for improved tissue penetration and bioavailability, making them viable candidates for subcutaneous delivery. Moreover, by incorporating covalent warheads, the team developed irreversible inhibitors, ensuring long-lasting therapeutic effects. (2) Beyond oncology, this scaffold technology is unlocking new frontiers in intracellular drug delivery. Traditionally, peptide-based therapeutics have struggled to cross cell membranes, limiting their application to extracellular targets. However, these researchers have shown that designed β-hairpin peptides can achieve passive membrane permeability, opening the door to intracellular PPI inhibitors. (3) The results showed that several of these large β-hairpin peptides successfully crossed artificial membranes, despite their size far exceeding the limits set by Lipinski’s “rule of five,” which typically predicts poor permeability for large molecules. A circular dichroism study provided another clue that these peptides changed their structure when moving from water to lipid environments, suggesting their ability to dynamically adjust their shape to cross membrane efficiently. This study has profound implications for tackling diseases driven by intracellular interactions, such as inflammatory diseases, viral infections (HIV, SARS-CoV-2) and potentially neurodegenerative disorders (Alzheimer’s, Parkinson’s). Indeed, we believe these studies represent more than just a step forward—it is a shift toward a new wave of biologically inspired peptides following the footsteps of cyclic β-sheets (Spexis), helices (Parabilis Medicines), and bicyclic peptides (Bicycle Therapeutics) to deliver smaller, more potent, and more precise than ever before peptide therapeutics.

These discoveries have real-world needed applications that could advance biotechnology and medicine. One particularly promising area is in biosensors and diagnostic tools where ADAPTins could be used to develop highly selective molecular probes, allowing clinicians to detect biomarkers with incredible accuracy even in complex biological samples. In oncology, these engineered peptides might pave the way for the next generation of immune checkpoint blockers, providing new alternatives to existing drugs like pembrolizumab and nivolumab. Unlike some antibodies, ADAPTins might be formulated for subcutaneous delivery, making them not only affordable, effective, but also more accessible to patients.

“Ongoing studies will deepen our current understanding of CDR-H3 loop structures and open doors for designing synthetic antibody fragments, which could serve as more economical and more scalable alternatives to monoclonal antibodies.” Stéphane Roche, CEO of AdaptBio Therapeutics.

By engineering some the best attributes of antibodies into small molecules, AdaptBio’s ADAPTins promise a new class of therapeutics that are smaller, more stable, and highly targeted. The company is actively developing anti-PD(L)1, anti-CD20/CD40, and anti-IL4a/IL17a/F inhibitors, targeting diseases with high unmet medical needs. Furthermore, AdaptBio Therapeutics is also pioneering peptide-based vaccines, leveraging the adaptability of its platform to create constrained epitopes embedded in hairpin peptides. Whether in oncology, immunology, or inflammatory diseases, AdaptBio is taking on the race to transform these novel peptide therapeutics into the drugs of tomorrow.